United States, China, and United Kingdom Lead the Global AI Ranking According to Stanford HAI’s Global AI Vibrancy Tool
21.11.2024 14:00:00 CET | Business Wire | Press release
India and the United Arab Emirates round out the top five in global AI leadership rankings
The Stanford Institute for Human-Centered AI (HAI) AI Index today released its Global AI Vibrancy Tool which allows flexible comparisons of 36 countries based on 42 openly available AI-specific indicators. Comparisons between countries can be made using either absolute or per capita versions of the indicators and are supported by interactive visualizations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241121006002/en/

Graphic: Stanford Institute for Human-Centered Artificial Intelligence (HAI)
The Global AI Vibrancy Tool measures the strength of the AI ecosystems based on 8 pillars — research and development, responsible AI, economy, education, diversity, policy and governance, public opinion, and infrastructure — with indicators including AI journal publications, total AI private investment, AI legislation passed, and foundation model datasets.
It is designed to empower policymakers, industry leaders, researchers, and the public with actionable, data-driven insights into national AI development that allows audiences to explore the findings in a way that’s most relevant to their goals. Policymakers can use the tool to strategically guide policy decisions, enterprises can gain insights into global AI market trends, and the general public can access concrete data to better understand the evolving debates around AI.
The Global AI Vibrancy Tool is available now at https://aiindex.stanford.edu/vibrancy/. The Stanford HAI AI Index hopes to further encourage global stakeholders to improve their data collection and sharing efforts in the interest of improving visibility into the global AI ecosystem. Regular updates will ensure the tool remains a valuable resource for tracking global AI development.
Using a set of weights determined by a panel of experts, this year’s top ten countries are as follows:
- United States: the U.S. leads the ranking by a significant margin and excels in the research and development (R&D) and in the AI economy pillars. The U.S. consistently produces the most notable AI machine learning models, attracts the highest levels of private AI investment, and leads in publishing responsible AI research.
- China: China demonstrates substantial strengths in the R&D, economy, and infrastructure pillars. China's focus on developing cutting-edge AI technologies and increasing its R&D investments has positioned it as a major AI powerhouse.
- United Kingdom: the U.K. demonstrates particular strength in the R&D, education, and policy and governance pillars.
- India: India has strong performance in R&D and recent improvements in the economy pillar.
- The United Arab Emirates: The U.A.E. scores highly on the economy pillar.
- France: France ranks sixth and shows strength in the policy and governance, education, and infrastructure pillars.
- South Korea: South Korea ranks seventh, scoring highly in the policy and governance, infrastructure, and public opinion pillars.
- Germany: Germany ranks eight, showing strength in the R&D, responsible AI, and education pillars.
- Japan: Japan demonstrates strong performance in the infrastructure, R&D, and economy pillars.
- Singapore: Singapore shows strength in the economy, diversity, and responsible AI pillars.
“AI has increased as a topic of national interest, and correspondingly narratives about which countries lead in AI have become more prominent than ever,” said Nestor Maslej, Project Manager of the AI Index. “However, there’s limited data providing a clear, quantitative view of where countries actually stand in AI. At the Index, we wanted to address this gap with a rigorous tool that could help policymakers, business leaders, and the public ground these geopolitical AI narratives in fact.”
About the AI Index
The AI Index report tracks, collates, distills, and visualizes data related to artificial intelligence (AI). Our mission is to provide unbiased, rigorously vetted, broadly sourced data in order for policymakers, researchers, executives, journalists, and the general public to develop a more thorough and nuanced understanding of the complex field of AI. The AI Index is recognized globally as one of the most credible and authoritative sources for data and insights on artificial intelligence.
About the Stanford Institute for Human-Centered AI (HAI)
The Stanford Institute for Human-Centered AI (HAI) is an interdisciplinary institute established in 2019 to advance AI research, education, policy, and practice. Stanford HAI brings together thought leaders from academia, industry, government, and civil society to shape the development and responsible deployment of AI. Stanford HAI’s mission is to advance AI research, education, policy, and practice to improve the human condition. We believe AI should be guided by its human impact, inspired by human intelligence, and designed to augment, not replace, people. Our interdisciplinary faculty conducts research focused on guiding the development of AI technologies intended to enhance human capabilities while ensuring its ethical, fair, and transparent use.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241121006002/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom